This application seeks funds from the National Center for Research Resources (NCRR) to support construction of the CIVD being established at the CHORI. The Center will consist of new laboratories, core facilities and office spaces suitable to house the research, research training and research support activities of several integrated scientific programs. The investigators who will occupy the Center conduct molecular, cellular and clinical studies in the inter-related areas of immunobiology, infectious diseases, pathogenesis, vaccine development and vaccine evaluation. As a group, the CIVD investigators have 18 extramural awards with total direct costs in year 2001 that exceed $3 million of which 75 percent derives from the National Institutes of Health (NIH). Dr. Dan Granoff will be the Scientific Director of the Center. Dr. Alexander Lucas, Deputy Director of Medical Research at CHORI, is the Principal Investigator (PI) and will be responsible for the space utilization and the administrative management of the Center. CHORI has made a substantial financial commitment to this project and has designated the CIVD as a high priority in its Strategic Plan. Approximately 8,000 sq. ft. of undeveloped shell space will be used for construction of the CIVD. The Center will provide interactive laboratory and office spaces as well as specialized shared core facilities, such as a Biosafety Level 3 (BSL3) facility and a DNA clean room for polymerase chain reaction (PCR) assembly. Construction of the CIVD will expand investigators' research capabilities, promote programmatic interaction and growth, increase training opportunities, and permit recruitment of additional scientists.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
Research Facilities Construction Grant (C06)
Project #
Application #
Study Section
Scientific and Technical Review Board on Biomedical and Behavioral Research Facilities (STRB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital & Res Ctr at Oakland
United States
Zip Code
Nolfi-Donegan, Deirdre; Konar, Monica; Vianzon, Vianca et al. (2018) Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab. Emerg Infect Dis 24:
Konar, Monica; Granoff, Dan M (2017) Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood 130:891-899
Lujan, Eduardo; Partridge, Elizabeth; Giuntini, Serena et al. (2017) Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine. Clin Vaccine Immunol 24:
Giuntini, Serena; Lujan, Eduardo; Gibani, Malick M et al. (2017) Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci. Clin Vaccine Immunol 24:
Partridge, Elizabeth; Lujan, Eduardo; Giuntini, Serena et al. (2017) The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C. Vaccine 35:4236-4244
Lujan, Eduardo; Pajon, Rolando; Granoff, Dan M (2016) Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice. Infect Immun 84:452-8
Giuntini, S; Granoff, D M; Beernink, P T et al. (2016) Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity. Clin Vaccine Immunol 23:698-706
Rossi, Raffaella; Konar, Monica; Beernink, Peter T (2016) Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H. Infect Immun 84:1735-1742
Granoff, Dan M; Giuntini, Serena; Gowans, Flor A et al. (2016) Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding. JCI Insight 1:e88907
Pajon, Rolando; Lujan, Eduardo; Granoff, Dan M (2016) A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine. Vaccine 34:643-649

Showing the most recent 10 out of 66 publications